ArticleScientific reports2022
Methicillin-resistant staphylococcus aureus nosocomial infection has a distinct epidemiological position and acts as a marker for overall hospital-acquired infection trends.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 42 citations in OpenAlex.
- Staphylococci: What Has Changed in the Antibiotic Resistance Profile in the Last Decade-Analysis of Strains Isolated from Hospitalised Patients.Pathogens (Basel, Switzerland) · 2025Article
- Bayesian inference of nosocomial meticillin-resistant Staphylococcus aureus transmission rates in an urban safety-net hospital.The Journal of hospital infection · 2025Article
- Virion content unpacked by long-read sequencing: stress-induced changes in transmitted staphylococcal mobilome due to phage-satellite interactions.Nucleic acids research · 2025Article
- MRSA in pig farming: the emerging role of flies in antimicrobial resistance: a cross-sectional study.Porcine health management · 2025Article
- Genetic Characterization ofToxins · 2025Article
- Bactericidal, Virucidal, and Biocompatible Properties of 3D Printed Materials Enhanced with Copper and Zinc Nanoparticles.Global challenges (Hoboken, NJ) · 2025Article
- Cationic Polymer Micelles as Carriers of Bioactive Sesquiterpene Lactones fromPharmaceutics · 2025Article
- The Study of Antistaphylococcal Potential of Omiganan and Retro-Omiganan Under Flow Conditions.Probiotics and antimicrobial proteins · 2025Article
- Environmental Risk Factors Contributing to the Spread of Antibiotic Resistance in West Africa.Microorganisms · 2025Review
- Activity-Based Protein Profiling Identifies an α-Amylase Family Protein Contributing to the Virulence of Methicillin-ResistantACS infectious diseases · 2025Article
- Medicinal plants: bioactive compounds, biological activities, combating multidrug-resistant microorganisms, and human health benefits - a comprehensive review.Frontiers in immunology · 2025Review
- Rising total leukocyte counts correspond with rising platelet counts in thrombotic thrombocytopenic purpura.Blood vessels, thrombosis & hemostasis · 2024Article
- Proposing an Affordable Plasma Device for Polymer Surface Modification and Microbial Inactivation.Molecules (Basel, Switzerland) · 2024Article
- Monophosphoryl lipid A as a co-adjuvant in methicillin-resistant Staphylococcus aureus vaccine development: improvement of immune responses in a mouse model of infection.Immunologic research · 2024Article
- A-Type Natriuretic Peptide Alters the Impact of Azithromycin on Planktonic Culture and on (Monospecies and Binary) Biofilms of Skin BacteriaMicroorganisms · 2023Article
- Review
- Antibiotic Susceptibility Profiling of Human PathogenicMicroorganisms · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An ongoing healthcare debate is whether controlling hospital-acquired infection (HAI) from methicillin-resistant Staphylococcus aureus (MRSA) will result in lowering the global HAI rate, or if MRSA will simply be replaced by another pathogen and there will be no change in overall disease burden. With surges in drug-resistant hospital-acquired pathogens during the COVID-19 pandemic, this remains an important issue. Using a dataset of more than 1 million patients in 51 acute care facilities across the USA, and with the aid of a threshold model that models the nonlinearity in outbreaks of diseases, we show that MRSA is additive to the total burden of HAI, with a distinct 'epidemiological position', and does not simply replace other microbes causing HAI. Critically, as MRSA is reduced it is not replaced by another pathogen(s) but rather lowers the overall HAI burden. The analysis also shows that control of MRSA is a benchmark for how well all non-S. aureus nosocomial infections in the same hospital are prevented. Our results are highly relevant to healthcare epidemiologists and policy makers when assessing the impact of MRSA on hospitalized patients. These findings further stress the major importance of MRSA as a unique cause of nosocomial infections, as well as its pivotal role as a biomarker in demonstrating the measured efficacy (or lack thereof) of an organization's Infection Control program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.